Alliance Global analyst James Molloy initiated coverage of NanoViricides with a Buy rating and $6 price target. NanoViricides is a nano-pharmaceutical company that specializes in creating novel treatments for viral infections, the analyst tells investors in a research note. The firm believes the opportunity for the company "could be significant" should NV-387 show positive data in the planned Phase 2 trials.
